Weekly Analysts’ Ratings Updates for Insmed (INSM)

Insmed (NASDAQ: INSM) recently received a number of ratings updates from brokerages and research firms:

  • 1/26/2018 – Insmed was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 1/25/2018 – Insmed was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $32.00 price target on the stock. According to Zacks, “Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company’s inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs. “
  • 1/24/2018 – Insmed was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company’s inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs. “
  • 1/18/2018 – Insmed was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company’s inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs. “
  • 1/17/2018 – Insmed is now covered by analysts at Credit Suisse Group AG. They set a “neutral” rating and a $31.00 price target on the stock.
  • 1/17/2018 – Insmed was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $35.00 price target on the stock. According to Zacks, “Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company’s inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs. “
  • 1/12/2018 – Insmed was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company’s inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs. “
  • 1/9/2018 – Insmed was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “buy” rating. They now have a $33.00 price target on the stock. According to Zacks, “Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company’s inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs. “
  • 1/4/2018 – Insmed had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
  • 1/4/2018 – Insmed had its “positive” rating reaffirmed by analysts at Robert W. Baird. They now have a $42.00 price target on the stock, up previously from $32.00.
  • 1/3/2018 – Insmed was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company’s inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs. “
  • 12/22/2017 – Insmed was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.

Insmed Incorporated (NASDAQ:INSM) opened at $27.76 on Monday. The company has a market cap of $2,130.00, a price-to-earnings ratio of -8.90 and a beta of 1.18. The company has a quick ratio of 15.21, a current ratio of 15.21 and a debt-to-equity ratio of 0.13. Insmed Incorporated has a 1-year low of $11.49 and a 1-year high of $33.94.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.69) EPS for the quarter, hitting analysts’ consensus estimates of ($0.69). equities analysts forecast that Insmed Incorporated will post -2.67 EPS for the current year.

In other Insmed news, Director Donald J. Hayden, Jr. sold 15,000 shares of the firm’s stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $32.50, for a total value of $487,500.00. Following the sale, the director now directly owns 71,131 shares in the company, valued at $2,311,757.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.03% of the company’s stock.

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).

Receive News & Ratings for Insmed Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply